

HANDBOOK OF PHARMACEUTICAL GENERIC DEVELOPMENT



VOLUME VII - Part One

Drug Development - Oral Suspension Dosage Forms

BLOCK J. D. & **BELLE D.**

Handbook of Pharmaceutical
Generic Development *Series*

HPGD ORAL SUSPENSION - Part I

First & Second Int. Edition - 01 & 02 (First & second print run) Published 1995/6/7/8.

Third International Edition - 03 (1st, 2nd and 3rd printing) - Published 1999/2000/2001.

Fourth International Edition - 04 (First & second print) - Jan / July 2002 & 2003.

Published and distributed in UK, US, EU, Israel, Asia, and Japan in by Locum International Publishing House (Houston, Israel, South Africa) in Hard Cover; Soft and Spiral Cover; Electronic CD ROM; and Online Editions. All print and electronic editions are identical in content and format.

Fifth International Edition - 05 (1st International Printing) - Publishing Date - January 2004

Sixth International Edition - 06 (1st Edition Printing) - Publishing Date - January 2005

Seventh International Edition - 07 (1st International Printing) - Publishing Date-January 2006

Copyright © 1995 Handbook of Pharmaceutical Generic Development.

Text Copyright © 1995 Handbook of Pharmaceutical Generic Development.

Illustration copyright © 1995 Handbook of Pharmaceutical Generic Development.

Locum International Group Publishing House 562 Monaco L Monaco Blvd. Delray Beach Florida 33446-1938 USA. - All right reserved

ISSN 0793 8659

ISSN 0793 8667 - Electronic Version (Online, CD ROM and e-mail PDF™ versions)

Handbook Development 24 volume series General **Generic** Development ISSN Series number 0793 7407 General **Generic** Development ISSN Series number 0793 7792 - Electronic Issue (Online and CD ROM are identical in size and content to the printed hard or soft cover version.)

Duplication: No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without the prior written permission of the copyright owner or subject to the following conditions:

Authorization to photocopy items for internal or personal use or internal or personal use of specific company personnel, is granted by Locum International Publishing House, provided that the base fee of \$1 per page is paid directly to the Copyright Clearance Center (CCC) 222 Rosewood Drive, Danvers, MA 01923 USA. For organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged.

For additional information, contact the Publications Department Locum International Publishing House; PO Box 874, 50 Gilad Street, Kochav Yair, 44864 Israel.



SERIAL NUMBER - DO NO REMOVE! - REGISTERED WITH

34004945-08

LOCUM INTERNATIONAL PUBLISHERS REGISTRATION SERVICES

Current Printing (last digit): 10 9 8 7 6 5

Canada Fax: +(1) 561-495 0585

US Fax: +(1) 561-431 2620

EU Fax: +(1) 561-431 2620

Global Orders Fax: +972 97-494 532

E-mail: info@locum.co.il

<http://www.locum.co.il>

<http://www.locumeuro.com>

<http://www.locumusa.com>

info@locumUSA.com

info@locumEuro.com

☒ PRINTED IN USA

PRINTED IN ISRAEL

PRINTED IN IRELAND

PRINTED IN REPUBLIC OF SOUTH AFRICA

ISBN 0793 **8632** - Electronic Version - Handbook Development 24 Volume Series
ISSN Series Number 0793 761X - Electronic Version.

Vol. 1 - Tablets Oral

Vol. 2 - Capsules Oral

Vol. 3 - Semisolids

Vol. 4 - Liquids Oral

Vol. 5 - SG Capsules

Vol. 6 - e-SOPs / SOPs

Vol. 7 - Suspensions

Vol. 8 - Eye & Nose

Vol. 9 - Aerosols MDI

Vol. 10 -Tablets CR / MR

Vol. 11 -Capsules ER

Vol. 12 - Tablets Oral DR

Vol. 13 - Analytical
(Top 50 Generic Assay Methods)

Vol. 14 - Tablets Oral

Vol. 15 - Capsules Oral

Vol.16 - Suspensions Oral

Vol. 17 - MF and MMI

Vol. 18 - MF and MMI

Vol. 19-SOPs/PAI-Checklist

Vol. 20 - Sterile Injections

Vol. 21 - Chew Tablets

For Drug Specific Handbooks refer to the 120+ Drug Development Series titled
READY-TO-GO™ DRUG DEVELOPMENT SERIES

PRODUCT DEVELOPMENT



Handbook of Pharmaceutical Generic Development

Oral Part One Suspensions



Locum *International* Publishers

Copyright © Locum Int. Publishing House Inc. All Rights Reserved.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming and recording, or by any information storage and retrieval system, without the permission of the publishers.

A Locum House Publication

INTRODUCTION

Handbook of Generic Drug Development - Oral Suspension Dosage Forms


This handbook is the newest updated and expanded international edition of the ongoing 24 volume *series* under the cumulative title of Handbook of Generic Drug Development. It is a hands-on, technical presentation that portrays the current drug requirement steps necessary at the time of going to print, of the Abbreviated New Drug Application for oral suspensions dosage forms. It is written in conjunction with Part Two of the Handbook which covers commercial development formulations and a development ANDA presentation as an example of the drug development process required for modern suspended oral dosage form.

The Handbook is available in print and electronic formats namely CD ROM and online **e-format**. The Handbook's know-how technology is written by industrial, agency and academic authorities and the full set of regulatory requirements are updated once annually in order to keep them current.

This handbook provides a proven pathway to suspended oral dosage form technology and development. Modern commercial formulations highlight the common development pathways to produce an appropriate granule for reconstitution. Examples are specially chosen to demonstrate the formulation steps and process stages as a prerequisite to developing stable, elegant, robust and rugged formulas.

This expanded current edition of the Handbook includes additional data on process and analytical method validation has been redesigned to meet the current Guidance for Industry - Organization of an Abbreviated New Drug Application as well as all FDA key draft and final guidelines and requirements of the Center of Drug Evaluation and Research (CDER) until current print date.

Editor-in-Chief.



ISSN 0973-8602
An on-going series

Additional Volumes in Preparation
General Drug Development Series ISSN 0973 7601
Electronic Drug Development Series ISSN 0973 761X



Acknowledgments


I.A.G.I.M. (R&D) Foundation.
 I.A.G.I.M. Research Council.
 Contributions - Generic & Research Firms
 Associate Universities, Technicians and Consultants.
 Handbook Series Coordinating Committee.
 International Journal of Drug Development.
 International Journal of Drug Formulation.
 Journal of Pharmaceutical Development.
 International Journal of Generic Drugs.
 International Journal of Drug R&D
 I.A.G.I.M. Drug Development Archives
 Locum International Archives.
 FDA/OGD/CDER Maryland
 Guides and Guidelines
 Library of Congress.
 AIC Conferences.
 Editorial Board.
 Pharm. Eur.
 USP/NF.
 USPC.
 BP.
 卐

*To Doribelle
 for her years of support and help
 to Sean for his expert knowledge on computerization
 to David and Ari for running the project's computers
 and lastly to Pat for his inestimable
 contribution.*

24 Volume Series
 Handbook of Pharmaceutical Generic Development
 International Edition

LOCUM PUBLISHING HOUSE





Contents


PHARMACEUTICAL DEVELOPMENT

<i>Table of Contents</i>	VIII
<i>Acronyms - Abbreviations</i>	XIII
Introduction	XIV
Preface	XV
Forward	XVI

Chapter	1
Regulatory	1.1
- Pre-formulation checklist	1.3
Getting the Right Documentation from A-Z	1.4
- SOP Control checklist	1.7
Development Notebooks	1.8
- Development Notebooks checklist	10
- SOP Control and Development Notebooks SOPs	11


Chapter	2
Developing the Formula -an Overview	2.1
- Formulation Check List	2.2
- Development formulations	2.3
Drug Development Checklist	2.4
Development Formula SOPs	2.5
Developing the Formula	2.7
Design Considerations for Reconstituted Suspensions	2.12
Product Development Flow Chart	2.29
Product Development Guide	2.31

Chapter	3
Active Ingredients	3.1
-Do's and Don'ts	3.2
-Active checklist	3.3
-Approved Suppliers Checklist	3.5
-Standard Operating Procedures, Actives	3.6
-Alternative Active Sources	3.7




Contents

Chapter	4
Semi active ingredients	4.1
-Validating the Semi-active ingredients, Checklist	4.2
Qualifying the Antioxidant	4.3
Antioxidant Tabulations	4.5
Non active materials (excipients)	4.12
-Checklist non active ingredient	4.14
-Standard Operating Procedures, Non actives	4.15
Purified Water - An ingredient for development	4.16
Chapter	5
Container closure systems	5.1
-Container-liner-closure systems, Checklist	5.3
-Container-liner-closure systems, SOPs	5.4
-Packaging Components	5.5
-Packaging Components Documentation Requirements SOP	5.12
Chapter	6
Manufacturing Instructions	6.1
- Manufacturing Instructions; Checklist	6.3
- The manufacturing Instructions and Controls	6.5
- Batch Manufacturing instructions	6.31
- In-process and Release Specifications	6.44
- Manufacturing Flow Charts	6.51
- Large scale manufacturing Instructions	6.52
- Large scale Master Formula	6.53
- Large scale Packaging Instructions	6.56
Chapter	7
In-process Quality Controls	7.1
-Manufacturing in-process controls; Checklist	7.3
-In-process Quality Control Summary	7.7
-In-process Quality Controls; SOPs	7.10
Chapter	8
Finished Product Specifications	8.1
- Finished Product Specifications example and Checklist	8.3
- Release and Check Specifications for Suspensions	8.6
- Release and Check Specifications - Special Considerations	8.8
- Glossary of Terms	8.10
- Finished Product Specifications; Required SOPs	8.12




Contents

Chapter	9
Process Optimization and Procedures	9.1
Evaluation product specifications	9.3
Qualification of Antioxidant and Chelating Agents	9.6
Qualification of Antioxidant Limits	9.7
Chapter	10
Scale-up Procedures	10.1
- Scale-up procedures; checklist	10.4
- Scale-up procedures; SOPs	10.5
Chapter	11
Cleaning Limits	11.1
Cleaning Limits Procedures; Checklist	11.6
Cleaning Validation Requirements; SOPs	11.8
Cleaning procedures as the FDA see it	11.9
Chapter	12
Analytical Validation Requirements	12.1
-Analytical Testing Out of Specification	12.21
-Analytical Testing Do's and Don'ts	12.23
-Out of Specification Checklists	12.24
-Out of Specification test Results	12.27
- The Ins and Outs of Outliers	12.36
-Impurities in Drug Substances	12.38
-Impurities Do's and Don'ts	12.50
-Impurities Glossary of terms	12.41
-Impurities Decision Trees	12.42
-Analytical Post approval Changes -PAC-ALTS	12.51
-PAC-ALTS Checklist	12.54
-Analytical Testing TLC ID & Impurity Methods	12.61
Analytical Testing Assay Method	12.69
-Ruggedness and Robustness	12.79
Chapter	13
Process Qualification Batch	13.1
-Process Qualification Batch; Checklist	13.2
-Process Qualification Batch; SOPs	13.3
-Process Qualification Blend Analysis	13.5
-Process Qualification Blend Analysis - Do's and Don'ts	13.7
- BUA blend Uniformity Analysis - Guidance	13.8
Content Uniformity Protocol	13.13



Contents

Chapter	14
Pivotal batch	
-The Pivotal Batch	14.1
-Pivotal batch Checklist	14.2
-Pivotal batch SOPs	14.3
-Sampling and Testing the Pivotal Batch	14.5
-Auditing the Pivotal batch	14.9
-Auditing the Pivotal batch Checklist	14.10
Chapter	15
Bioequivalence vs. RLD	15.1
Test Designs - Overview	15.3
Statistical Bioequivalence	15.13
IBE Equation explained	15.14
IBE Big Picture (Pros and Cons)	15.15
Comparing IBE and ABE	15.16
Generic Drug Dissolution and the RLD	15.19
Typical IVIVC Models	15.22
Dissolution Testing of IR Dosage Forms	15.24
Similarity Factor in dissolution testing	15.30
Biowaivers	15.32
Overall Dissolution Picture	15.36
Biopharmaceutics Classification System	15.37
Class One to Class four Drugs	15.38
Performance Verification in Dissolution testing	15.42
BA & BE - general Considerations	15.56
Food-Effects in BA-BE Studies	15.82
Bioanalytical Methods Validation	15.90
Bioanalytical Methods Validation Checklist	15.101
Dissolution testing of IR Solid Oral Dosage Forms & BCS	15.102
BioPharmaceutical Classification System	15.106
FDA Narrow therapeutic List	15.115
Similarity Testing - Chow, Pitt and Others	15.116
Chapter	16
Technical Transfer Documentation	16.1
-Technical Transfer Documentation; checklist	16.5
-Technical Transfer Documentation; Pharmaceutical Part	16.7
-Technical Transfer Documentation; Analytical Part	16.10
-Laboratory Equipment Installation & Operation Qualification	16.13



Contents

Chapter	17
Process Validation batches	17.1
-The Process Validation Batches; checklist	17.3
-Process Validation Requirements; SOPs	17.4
-Reserved page	17.5
-Process Validation Master Plan	17.6
-Bulk Suspension Single Fill	17.8
-Bulk Suspension Two Stage Fill	17.9
-Process Validation Master Protocol	17.10
-Process Validation Stability & Statistics	17.11
Chapter	18
Pre--Approval Inspections	18.1
PAI Summary	18.8
Pre--Approval Inspection Audit - Team Set Up	18.9
Pre--Approval Inspection Audit - Team Activities	18.11
Chapter	19
Stability Testing of Drug Substance and Drug Product I	19.1
Stability Commitment	19.8
Stability Protocol	19.9
Stability Summary - Results	19.10
Stability Reports	19.12
Stability Testing of Drug Substance and Drug Product II	19.17
Stability Testing of Drug Substance and Drug Product II	19.23
Stability Testing Significant Change SOP	19.27
Storage Conditions	19.31
Photostability	19.33
Chapter	20
Standard Operational Procedures	
Setting up a functional Stability Unit	20.1
Stability SOPs Development	20.9
Development SOPs - Training Tool	20.15
APPENDIX	
Development Guidances	20.21
Master Formula & Processes - Title 17 Series	



ISSN 0793 8632

An on-going series

Additional Volumes in Preparation

ISBN 0793 8640 - Electronic Version

Handbook Development 24 Volume Series

ISSN Series Number 0793 7792 - Electronic Version

Handbook of Pharmaceutical

Generic Development Series